Voyager Therapeutics (FRA:VT6) Ending Cash Position: €39.83 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VT6 Voyager Therapeutics Inc FRA:VT6
55 GF Score
Price €2.62
GF Value €1.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Ending Cash Position?

Voyager Therapeutics FRA:VT6 +2.19% 55 Ending Cash Position is €39.83 Mil as of Mar. 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 55/100 and a GF Value™ of €1.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Voyager Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was €39.83 Mil.

Voyager Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 (€43.23 Mil) to Dec. 2025 (€58.10 Mil) but then declined from Dec. 2025 (€58.10 Mil) to Mar. 2026 (€39.83 Mil).

Voyager Therapeutics's annual Ending Cash Position increased from Dec. 2023 (€64.55 Mil) to Dec. 2024 (€70.90 Mil) but then declined from Dec. 2024 (€70.90 Mil) to Dec. 2025 (€58.10 Mil).

Voyager Therapeutics Ending Cash Position Related Terms

Voyager Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Ending Cash Position Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 105.50 94.85 64.55 70.90 58.10

Voyager Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.81 40.59 43.23 58.10 39.83
FRA:VT6
55GF Score
Voyager Therapeutics Inc FRA:VT6
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Voyager Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=63.402+-5.299
=58.10

Voyager Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=58.851+-19.018
=39.83

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €39.83 Mil mean?
Voyager Therapeutics (FRA:VT6) has a Ending Cash Position of €39.83 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Ending Cash Position too high?
Voyager Therapeutics' current Ending Cash Position is €39.83 Mil. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Ending Cash Position compare to KROS and CDXS?
Voyager Therapeutics' Ending Cash Position of €39.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Ending Cash Position is €39.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.37, compared to a current price of €2.62 — trading 90.9% above its estimated fair value. The current Ending Cash Position is €39.83 Mil. Voyager Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Ending Cash Position is €39.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €2.62 is trading 90.9% above its estimated GF Value™ of €1.37. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Ending Cash Position: €39.83 Mil
  • GF Value™: €1.37 vs. price of €2.62 (90.9% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score

Get the complete analysis for FRA:VT6

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.62
Price
€1.37
GF Value